Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Xu Che

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0936-0817; OpenAlex author ID A5100782571. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
87
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 4 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 27

  1. Metabolic signatures of lipid dysregulation and inflammation characterize pancreatic cancer risk in type 2 diabetes mellitus and improve risk stratification: a… Co-author DOI 10.1016/j.diabres.2026.113230↗
  2. Elevated circulating glycine levels are associated with reduced pancreatic cancer risk: A prospective cohort study based on the UK biobank. Co-author DOI 10.1016/j.pan.2025.12.015↗
  3. Association between female reproductive factors and new-onset pancreatic cancer risk: a prospective cohort study. Last author DOI 10.1097/cej.0000000000000987↗
  4. PPP3CB inhibits pancreatic cancer progression by promoting ATOH8 translocation and transcriptionally regulating Sp1. Co-author DOI 10.1016/j.lfs.2025.123631↗
  5. Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients. Last author DOI 10.1016/j.pan.2025.11.004↗
  6. Spatial transcriptomics in pancreatic cancer: Advances, prospects and challenges. Last author DOI 10.1016/j.critrevonc.2024.104430↗
  7. Clinicopathological Features, Immune Infiltration Landscape and Involved Signaling Pathways of the desmogleins family in Pancreatic Adenocarcinoma Last author DOI 10.21203/rs.3.rs-2971625/v1↗
  8. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Co-author DOI 10.1038/s41392-021-00769-z↗
  9. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  10. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  11. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  12. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  13. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Co-author DOI 10.7150/thno.23978↗
  14. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. Co-author DOI 10.1038/s41598-017-08794-1↗
  15. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Co-author DOI 10.1158/1535-7163.mct-16-0452↗
  16. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2016.10.02↗
  17. Body mass index does not affect the survival of pancreatic cancer patients. Co-author DOI 10.3748/wjg.v23.i34.6287↗
  18. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Co-author DOI 10.1038/ng.3568↗
  19. Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: Retrospective cohort study, 7-year ex… First author DOI 10.1097/md.0000000000004861↗
  20. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population. Co-author DOI 10.7754/clin.lab.2015.150329↗
  21. Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer. Co-author PMID 25932223↗
  22. [Application value of core needle biopsy technique in the pathological diagnosis of locally advanced pancreatic cancer]. Co-author PMID 26081211↗
  23. Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization. Co-author DOI 10.1371/journal.pone.0114616↗
  24. [Early complications of intra-operative radiotherapy in locally advanced pancreatic cancer]. First author PMID 25241794↗
  25. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Co-author DOI 10.1093/carcin/bgt004↗
  26. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗
  27. [Value of intraoperative radiotherapy in the treatment of locally advanced pancreatic cancer]. Co-author PMID 21418868↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yunlong Li · 5 shared papers, 2024–2026 · strength 1.48
  2. Yongxing Du · 5 shared papers, 2023–2026 · strength 1.45
  3. Shuai Xiang · 4 shared papers, 2025–2026 · strength 1.26
  4. Chengfeng Wang · 4 shared papers, 2014–2026 · strength 0.68
  5. Jianwei Zhang · 8 shared papers, 2011–2019 · strength 0.43
  6. Chen Hsuan Wu · 7 shared papers, 2011–2021 · strength 0.41
  7. Dongxin Lin · 7 shared papers, 2011–2021 · strength 0.41
  8. Yingtai Chen · 7 shared papers, 2014–2019 · strength 0.41
  9. Jian Zheng · 5 shared papers, 2016–2021 · strength 0.37
  10. Lei Zheng · 4 shared papers, 2017–2021 · strength 0.37
  11. Shuisheng Zhang · 3 shared papers, 2016–2025 · strength 0.36
  12. Rufu Chen · 4 shared papers, 2019–2021 · strength 0.34
  13. Chengfeng Wang · 5 shared papers, 2014–2021 · strength 0.32
  14. Shanglong Liu · 1 shared paper, 2026 · strength 0.32
  15. Xudong Huang · 4 shared papers, 2016–2021 · strength 0.31
  16. Chengfeng Wang · 5 shared papers, 2011–2021 · strength 0.29
  17. Yanfen Zheng · 3 shared papers, 2019–2021 · strength 0.26
  18. Ying Ye · 3 shared papers, 2019–2021 · strength 0.26
  19. Jiachun Su · 3 shared papers, 2019–2021 · strength 0.26
  20. Jialiang Zhang · 3 shared papers, 2019–2021 · strength 0.26
  21. Ling Pan · 3 shared papers, 2019–2021 · strength 0.26
  22. Shunda Wang · 1 shared paper, 2025 · strength 0.26
  23. Junjie Hang · 1 shared paper, 2025 · strength 0.24
  24. Lixia Wu · 1 shared paper, 2025 · strength 0.24
  25. Tao Liu · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.